Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
about
The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyAnticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionAdrenocortical carcinoma: the management of metastatic disease.Curcumol Inhibits Growth and Induces Apoptosis of Colorectal Cancer LoVo Cell Line via IGF-1R and p38 MAPK Pathway.IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibodyImproving the outcome for children with cancer: Development of targeted new agents.Complement component 1, q subcomponent binding protein is a marker for proliferation in breast cancer.Moderate Hypoxia Exhibits Increased Endothelial Progenitor Vessel-forming Ability However Gestational Diabetes Caused to Impede Compensatory Defense ReactionPaeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 PhosphorylationIGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insightsAddiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.Molecular mechanisms of chemoresistance in osteosarcoma (Review).Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells.Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression.Heterozygous nonsense mutations near the C-terminal region of IGF1R in two patients with small-for-gestational-age-related short stature.
P2860
Q27000467-1A474E2B-33BF-41D5-8C40-EBEE027F9BBDQ35050195-85A9BC42-A126-44C5-90DD-9E2C66E56442Q35767389-48D7019F-8B64-42C4-A404-E21DA75E0294Q36081865-C29384D8-98D4-491F-B8BB-185920C54798Q36088751-961D9151-80B5-44AB-AC04-C1E280D69237Q36105608-494E5BFD-A531-4139-A1BB-CD4EA5DC569EQ36169762-8C076226-59FE-4709-A808-C12D8ECA240DQ36238795-8120CFA3-5046-4BE5-B2F0-CF10BA67F4BAQ37071560-7AC012B2-784D-476A-B43E-5B5A559C416DQ37126587-48011648-09AB-4C44-9CB7-04030EF67D2BQ37243523-1CFA0248-70C7-4247-983C-9757848666C7Q37615933-CC88391A-8AB8-46B9-8006-169B90752FBAQ37685442-7AC651C5-95A1-4C4E-A222-934A1AC97BD0Q37719938-A35BE311-6875-4C8C-94B1-F1403CF34E3DQ38113988-7B26B64E-4C87-4CA2-8CF8-3CD555158934Q38989374-7D2C4DBC-86F3-4FEE-85C0-B28163AF5FADQ39626598-918B0B45-E703-4FA3-90F4-57E5ABC61AC6Q40229111-653D2498-87F7-48EF-9CC7-E9083FDAF598Q42119362-C17E3D37-BB43-42DE-A1E7-B38754404F55Q48251105-D5CCECC9-B9A6-4097-9203-2D6EC42C099FQ52952095-E0DAE938-3665-40DF-A381-27EE96A21257
P2860
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Clinical development of insuli ...... inhibitors: at the crossroad?
@ast
Clinical development of insuli ...... inhibitors: at the crossroad?
@en
type
label
Clinical development of insuli ...... inhibitors: at the crossroad?
@ast
Clinical development of insuli ...... inhibitors: at the crossroad?
@en
prefLabel
Clinical development of insuli ...... inhibitors: at the crossroad?
@ast
Clinical development of insuli ...... inhibitors: at the crossroad?
@en
P2093
P2860
P921
P1476
Clinical development of insuli ...... inhibitors: at the crossroad?
@en
P2093
Ahmad Awada-Hussein
Andrea Gombos
Lissandra Dal Lago
Otto Metzger-Filho
P2860
P2888
P304
P356
10.1007/S10637-012-9811-0
P577
2012-03-14T00:00:00Z
2012-12-01T00:00:00Z